NCT07218770View on ClinicalTrials.gov

A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 15, 2025

Primary Completion Date

April 28, 2028

Study Completion Date

April 28, 2028

Conditions
Active Noninfectious Uveitis Affecting the Posterior Segment
Interventions
DRUG

REGN7041

Administered as per the protocol

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT07218770 - A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants | Biotech Hunter | Biotech Hunter